Status:
COMPLETED
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Lead Sponsor:
MedImmune LLC
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimuma...
Eligibility Criteria
Inclusion
- Male and female subjects
- 18 years and older
- Histologic confirmation of advanced solid tumors
- Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.
Exclusion
- Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment
- Active or prior documented autoimmune disease within the past 2 years
- Current or prior use of immunosuppressive medication within 14 days with some exceptions.
Key Trial Info
Start Date :
October 13 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2020
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT02261220
Start Date
October 13 2014
End Date
January 27 2020
Last Update
March 6 2020
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85258
2
Research Site
Duarte, California, United States, 91010
3
Research Site
La Jolla, California, United States, 92093
4
Research Site
Los Angeles, California, United States, 90025